The PHN is informing primary care providers that on 24/11/2023, the Public Health and Surveillance Branch in the Office of Health Protection of the Department of Health and Aged Care has issued a quarantine notice for the product; InterPharma Sodium Chloride 0.9% 10ml or 30ml ampoules.
SafeScript NSW’s new approval management functionality will mean that prescribers (medical, nurse and dental practitioners) will be able to apply online for approval to prescribe or supply certain Schedule 8 medicines (in some cases, be issued approvals in real time), monitor application progress, view patient approval (previously referred to as an authority) history, have visibility of the number of active approvals held and see all approvals held within their organisations.
The NSW Ministry of Health has updated the requirements to prescribe Schedule 8 psychostimulant medicines (dexamfetamine, lisdexamfetamine and methylphenidate). These changes recognise the scope of practice and expertise of psychiatrists, paediatricians and neurologists and are intended to reduce burden on patients, carers and families.
SafeScript NSW, the state’s real time prescription monitoring (RPTM) system, has implemented a range of new enhancements aimed at improving the overall user experience.
From 1 July 2023, ODT medicines will become part of the Section 100 Highly Specialised Drugs (HSD) Program (Community Access) arrangements. This means ODT medicines will be dispensed in the same way as other community access Section 100 HSD Program medicines from section 90 approved community pharmacies, section 92 approved medical practitioners, and section 94 approved hospital authorities (public and private).